MARKET

SRNE

SRNE

Sorrento Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.450
-0.080
-5.23%
Closed 16:00 11/18 EST
OPEN
1.520
PREV CLOSE
1.530
HIGH
1.570
LOW
1.450
VOLUME
1.56M
TURNOVER
--
52 WEEK HIGH
6.50
52 WEEK LOW
1.390
MARKET CAP
189.95M
P/E (TTM)
-0.6712
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SRNE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SRNE News

  •  Sorrento CEO to Present at Upcoming Investor Conferences
  • GlobeNewswire.6d ago
  • Sorrentto Therapeutics Inc (SRNE): Are Hedge Funds Right About This Stock?
  • Insider Monkey.11/07 22:05
  • Sorrento to Present New Data on Advanced Immunotherapies at ASH 2019 and Other Conferences
  • Benzinga.11/07 08:27
  • Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
  • GlobeNewswire.11/07 00:37

More

Industry

Biotechnology & Medical Research
+0.32%
Pharmaceuticals & Medical Research
+0.13%

Hot Stocks

Name
Price
%Change

About SRNE

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.
More

Webull offers Sorrento Therapeutics Inc (SRNE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.